According to Cold Chain IQ findings, nearly 30% of individuals surveyed reported temperature excursions (differences in temperature relating to environmental factors) in 6% or more of their temperature-sensitive pharmaceutical product.
Temperature excursions of pharmaceutical products can not only result in product losses, but also endanger patient lives.
Cold Chain IQ has published the state of the industry report Operating a Global Temperature-Controlled Supply Chain. This report examines temperature excursions in the distribution chain for clinical and commercial products and leading strategies the pharmaceutical industry is employing to improve storage and handling of temperature-sensitive products.
Over the past year, Cold Chain IQ conducted interviews with more than 100 experts from all stages of the pharmaceutical and medical distribution chain from logistics to quality assurance, regulators to manufacturers.
Contributors to the report include global heads of cold chain and experts from Latin America IMF, Pfizer, Word Courier Group, Roche, Eli Lilly, Modality Solutions, AMAG, Merck, Exelsius Cold Chain, Novo Nordisk, DHL, MacroGenics, Laminar Medica, Logistics Institute of Asia Pacific, and the South African Refrigerated Distribution Association. Also included is a perspective from 300-plus attendees of the 11th annual Cool Chain Logistics Europe industry forum.
The 28-page report features these findings:
•96% consider cold chain or temp control a core competency of their logistics provider.
•BRIC (Brazil, Russia, India, and China) in five years: China will present the greatest opportunity.
•63% said finding cost-effective solutions/products is their key challenge in the storage and distribution of CRT and ambient products.
•71% of pharmaceutical distribution professionals plan to increase investment over the next 10 years.
To learn more, read the full report here.
